WEGOVY
Pharma companies announce direct-to-consumer sales and price cuts in US
Several pharmaceutical companies are now selling drugs directly to U.S. patients and offering significant discounts, responding to President Trump's push to lower prescription costs and eliminate intermediaries. These initiatives include deals for tariff relief in exchange for price reductions and the launch of new direct-to-consumer sales platforms.
Trump says price of Ozempic will be lowered
President Donald Trump announced that the price of Novo Nordisk's popular weight-loss drug will be significantly reduced. Negotiations for price changes are expected to be rapid. The company has engaged in discussions with the administration regarding drug pricing. The focus remains on improving patient access and affordability of these medications.
Pharma companies announce direct-to-consumer sales and price cuts in US
Several drug makers are now selling medicines directly to Americans. This move follows President Trump's push to reduce prescription drug prices. Companies like AbbVie, AstraZeneca, and Pfizer are offering discounts. A new government website, TrumpRx.gov, is planned for early 2026. Patients will soon have more options to access affordable medications.
Cardiologists reveal the number 1 afternoon habit that can slash your cholesterol
Cardiologists suggest a simple afternoon habit to help lower cholesterol. Reaching for a fiber-rich snack is key. Fiber aids in reducing bad cholesterol and supports a healthy weight. It also combats inflammation and promotes stable blood sugar levels. Incorporating these snacks can lead to significant improvements in heart health over time. Other tips include exercise and limiting unhealthy fats.
US stock futures: Dow, S&P 500, Nasdaq steady after record highs as gold nears $4,100, Nvidia gains export boost, TSMC revenue surges 30% — is a Fed rate cut next?
US stock futures held steady Thursday after a record-setting rally. S&P 500 futures stayed flat as investors await more Fed rate cuts. Nasdaq and Dow futures also showed little change. Market optimism rose after the Fed’s September meeting minutes hinted at possible interest-rate cuts this year. No major economic reports ahead due to the government shutdown. Traders will watch key earnings from Delta Air Lines and PepsiCo.
Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launch
Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within six months of its March launch. The weight-loss and diabetes medication posted ₹80 crore in September sales, surpassing popular brands and attributed to its superior efficacy and first-mover advantage over competitors.
- Go To Page 1
Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of key drugs like Mounjaro. This strategic move leverages India's skilled workforce and includes a new Hyderabad facility to oversee contract manufacturing, despite global shifts towards US production.
Costco to sell Ozempic and Wegovy at huge discounts — even if you don’t have insurance
Costco offers huge Ozempic and Wegovy discounts. Members can save on these diabetes and weight loss medications. The program makes life-changing treatments affordable and easily accessible for everyone, even without insurance.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.
US Pfizer deal powers European health stocks as Trump policy haze clears
European healthcare stocks jumped on Wednesday, mirroring moves in the United States, propelled by a deal between Pfizer and President Donald Trump to lower prescription drug prices in the Medicaid programme in exchange for tariff relief.
Weight-loss drug Ozempic to debut in India soon
Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive market against Eli Lilly's Mounjaro. Novo Nordisk's Wegovy also competes. The company's semaglutide patent expires next year, allowing generic versions. India has a large population with diabetes and obesity. Ozempic offers significant health benefits.
India's Fortis to expand obesity clinics amid weight-loss therapy boom, CEO says
Fortis Healthcare will expand its obesity clinic network. This decision follows increased demand for weight management solutions. Popular weight-loss drugs have boosted patient awareness. The company will add thirteen clinics across several states. These clinics will offer comprehensive programs. The Indian obesity drug market has seen significant growth. Fortis also plans a major investment in hospital expansion.
Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs up
Stock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion.
After Mounjaro Jab, Eli Lilly plans weight loss pill launch in India
Eli Lilly plans to launch an oral weight loss drug, orforglipron, after Mounjaro's India success. Regulatory submissions are expected soon, with potential approvals by 2026. This pill targets a broader patient group than injectables. Studies show orforglipron offers better weight loss and glucose control compared to Novo Nordisk's oral semaglutide.
Wegovy-maker Novo Nordisk starts 'fight back' as investors return
Novo Nordisk aims to regain its position in the weight-loss drug market. The company's shares are rising after a restructuring plan. CEO Mike Doustdar is streamlining the business. Novo is promoting research on semaglutide. Investors are watching for improved execution in the United States. Analysts believe the company is positioning itself to compete with Eli Lilly.
S&P, Nasdaq hit record highs as Fed signals more easing; Intel, Nvidia surge
Wall Street is nearing record highs, driven by a tech stock surge. Nvidia and Intel's $5 billion partnership boosts the market. Economic reports lift Treasury yields. The Federal Reserve's interest rate cut aims to stimulate the slowing job market. Novo Nordisk's weight-loss drug shows promising results. Cracker Barrel and Darden Restaurants face profit concerns. International markets show mixed performance.
Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiry
Indian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's and Macleods are among the firms preparing. They aim to tap into a large global market. However, they will face competition from Chinese companies. Securing quality materials and scaling up production are key challenges.
US stock market today reverse gains: Dow, S&P 500 and Nasdaq pull back from record highs as retail sales surge and Fed rate decision looms
US stock market experienced a modest pullback on Tuesday as investors balanced optimism from strong consumer spending against uncertainty ahead of the Federal Reserve’s much-anticipated policy meeting. Despite the slight declines in major indexes, economic data revealed robust retail sales in August, rising 0.6%, well above expectations. This indicates that American consumers remain resilient even as inflation persists and the labor market shows signs of softening.
Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions
Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to treat conditions like knee osteoarthritis and sleep apnea. Clinical trials are planned to investigate the impact of CagriSema and amycretin on various obesity-related comorbidities.
Experience cocktail hours
Products and services are converging into 'experience cocktails,' blending physical goods with human-mediated interactions. This shift is evident across industries like ride-hailing, wellness, and e-commerce, where integrated brand value propositions are reshaping consumer expectations. AI's emergence further personalizes these experiences, creating predictive gratification and accelerated service metrics, ultimately influencing the future of consumption and transactions.
WHO adds popular weight-loss drugs to essential medicines list
The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines. This decision could significantly lower the prices of these medications in countries like India, where obesity rates have surged. The WHO aims to improve access and health outcomes by prioritizing those in need and encouraging generic competition.
European shares rise as Inditex leads retailers, Novo Nordisk shines
European shares experienced a rise, propelled by strong performances in the retail sector, particularly Inditex, which reported accelerated sales. Novo Nordisk also saw gains following its restructuring announcement, including workforce reductions, aimed at enhancing competitiveness. Tech stocks contributed to the positive sentiment, with SAP and ASML climbing after Oracle's optimistic cloud order projections.
Novo Nordisk to cut 9,000 jobs in restructuring
Novo Nordisk, the maker of Wegovy, plans a major restructuring. The company will cut 9,000 jobs globally. This move aims to save 8 billion Danish crowns annually. The restructuring will simplify the organisation. It will also speed up decision-making. Novo Nordisk faces increasing competition from Eli Lilly.
Ahead of Market: 10 things that will decide stock market action on Tuesday
Indian markets rebounded on Monday after three sessions of losses, driven by stronger-than-expected 7.8% GDP growth and relief from a U.S. court ruling on Trump’s tariffs. Analysts highlighted optimism in autos and consumer durables but cautioned on GST and borrowing risks.
European stocks rise as Novo Nordisk lifts healthcare on Wegovy data
Shares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison.
Weight-loss drugs are trending for rapid results, but new study reveals an unexpected benefit; with a catch
A recent study published in JAMA Dermatology suggests that GLP-1 medications like Ozempic and Wegovy, commonly used for weight loss and diabetes, may also reduce symptoms of hidradenitis suppurativa, a painful skin condition. Among 66 patients followed for 18.5 months, 67% reported fewer flares and 60% experienced less pain. Experts caution that while promising, these drugs are not approved for skin conditions and off-label use requires medical guidance.
Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes
Eli Lilly's new pill shows promise. The drug helped people with diabetes lose weight in trials. The pill, orforglipron, led to a 10.5% weight loss. This is for adults struggling with obesity and type 2 diabetes. The company is seeking approval from regulators. Lilly views the pill as a promising alternative to injections. The results also showed improved heart-risk markers.
IMA warns of misuse, mis-prescription of new weight-loss drugs, such as Wegovy and Mounjaro
The Indian Medical Association is raising concerns about the misuse of weight-loss drugs like Wegovy and Mounjaro, urging stricter prescription controls. They plan to petition the health ministry and drug regulator, advocating for prescriptions to be limited to certified endocrinologists or diabetologists. Rampant prescriptions by cosmetologists and other non-specialists are fueling concerns about potential side effects and improper usage.
Riding high on Wegovy, Novo Nordisk doubled its workforce. Now layoffs loom
Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's workforce nearly doubled in five years, but slowing sales and increased competition are now putting pressure on costs. A hiring freeze is in place, and analysts anticipate cuts, particularly in sales, as Novo seeks to regain market share and improve profitability.
Load More
